32
Participants
Start Date
November 30, 2002
Primary Completion Date
February 29, 2004
Study Completion Date
February 29, 2004
risedronate
0.23 mg 14C-labeled risedronate, followed 7 days later with oral 35 mg risedronate once a week for 52 weeks followed by another 14C-labeled risedronate followed weekly by 35 mg risedronate for 3 weeks
alendronate
0.45 mg 14C-labeled alendronate, followed 7 days later with oral 705 mg alendronate once a week for 52 weeks followed by another 14C-labeled alendronate followed weekly by 70 mg alendronate for 3 weeks
Research Facility, Gainesville
Research Site, New Orleans
Lead Sponsor
Collaborators (1)
Sanofi
INDUSTRY
Warner Chilcott
INDUSTRY